Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 7/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915608 | 0.88 | AR (0.56) | NPC1RAB9AARALOX5MAPT | |
| SCHEMBL1916179 | 0.86 | AR (0.56) | NPC1RAB9AARALOX5MAPT | |
| SCHEMBL1916862 | 0.85 | NPC1 (0.55) | NPC1RAB9AARMAPTMEN1 | |
| SCHEMBL14048212 | 0.84 | NPC1 (1.00) | NPC1RAB9AARALOX5MAPT | |
| SCHEMBL1915793 | 0.83 | NPC1 (0.54) | NPC1RAB9AARALOX5MAPT | |
| SCHEMBL1915767 | 0.83 | MEN1 (0.58) | NPC1RAB9AARALOX5MAPT | |
| SCHEMBL1916049 | 0.83 | AR (0.52) | NPC1RAB9AARMAPTMEN1 | |
| SCHEMBL1915486 | 0.82 | NPC1 (0.54) | NPC1RAB9AARMAPTMEN1 | |
| SCHEMBL2399679 | 0.82 | AR (0.51) | NPC1RAB9AARMAPTMEN1 | |
| SCHEMBL1916379 | 0.81 | NPC1 (0.58) | NPC1RAB9AARMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | NPC1 28/4885RAB9A 1681/4885AR 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.